{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:19:31Z","timestamp":1778685571551,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00520-026-10605-1","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:22:55Z","timestamp":1775546575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world incidence of nausea and vomiting induced by antineoplastic agents: insights and future directions from the Japanese adverse drug event report database"],"prefix":"10.1007","volume":"34","author":[{"given":"Hajime","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"10605_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMra0706547","journal-title":"N Engl J Med"},{"key":"10605_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"10605_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.autneu.2016.07.003","volume":"202","author":"CD Balaban","year":"2017","unstructured":"Balaban CD, Yates BJ (2017) What is nausea? A historical analysis of changing views. Auton Neurosci 202:5\u201317. https:\/\/doi.org\/10.1016\/j.autneu.2016.07.003","journal-title":"Auton Neurosci"},{"key":"10605_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1756283X15618131","volume":"9","author":"P Singh","year":"2016","unstructured":"Singh P, Yoon SS, Kuo B (2016) Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol 9:98\u2013112. https:\/\/doi.org\/10.1177\/1756283X15618131","journal-title":"Ther Adv Gastroenterol"},{"key":"10605_CR5","volume-title":"version 2","author":"Japan Society of Clinical Oncology Clinical practice guidelines for antiemesis","year":"2015","unstructured":"Japan Society of Clinical Oncology Clinical practice guidelines for antiemesis (2015) version 2. Kanehara & Co., Ltd"},{"issue":"Supplement 1","key":"10605_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00520-018-4147-8","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-introduction. Support Care Cancer 26(Supplement 1):3\u20134. https:\/\/doi.org\/10.1007\/s00520-018-4147-8","journal-title":"Support Care Cancer"},{"key":"10605_CR7","volume-title":"version 1","author":"Japan Society of Clinical Oncology Clinical practice guidelines for antiemesis","year":"2010","unstructured":"Japan Society of Clinical Oncology Clinical practice guidelines for antiemesis (2010) version 1. Kanehara & Co., Ltd"},{"key":"10605_CR8","volume-title":"version 3","author":"Japan Society of Clinical Oncology Clinical practice guidelines for antiemesis","year":"2023","unstructured":"Japan Society of Clinical Oncology Clinical practice guidelines for antiemesis (2023) version 3. Kanehara & Co., Ltd"},{"key":"10605_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, CINV Study Group of Japan (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865. https:\/\/doi.org\/10.1007\/s10147-015-0786-7","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10605_CR10","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(3):2343\u20132351. https:\/\/doi.org\/10.1056\/NEJMoa032709","journal-title":"N Engl J Med"},{"issue":"5","key":"10605_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Y Shimada","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11(5):909\u2013913. https:\/\/doi.org\/10.1200\/JCO.1993.11.5.909","journal-title":"J Clin Oncol"},{"issue":"5","key":"10605_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bulcan.2021.01.010","volume":"108","author":"A Rambeau","year":"2021","unstructured":"Rambeau A, Cherifi F, Neviere Z, Licaj I, Clarisse B, Joly F (2021) Platinum-induced nausea and vomiting in patients treated for head and neck cancer. Bull Cancer 108(5):449\u2013454. https:\/\/doi.org\/10.1016\/j.bulcan.2021.01.010","journal-title":"Bull Cancer"},{"key":"10605_CR13","doi-asserted-by":"publisher","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23\u201344. https:\/\/doi.org\/10.1016\/j.clinthera.2005.01.005doi:10.1016\/j.clinthera.2005.01.005","DOI":"10.1016\/j.clinthera.2005.01.005doi:10.1016\/j.clinthera.2005.01.005"},{"key":"10605_CR14","first-page":"1035","volume":"25","author":"T Taguchi","year":"1998","unstructured":"Taguchi T, Morimoto K, Horikoshi N, Takashima S, Toge T, Kimura M, Sano M, Aoyama H, Ota J, Noguchi S, S-1 Cooperative Study Group (Breast Cancer Working Group) (1998) An early phase II clinical study of S-1 in patients with breast cancer. Gan To Kagaku Ryoho 25:1035\u20131043","journal-title":"Gan To Kagaku Ryoho"},{"key":"10605_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1248\/yakushi.20-00196-4","volume":"141","author":"Y Kiryu","year":"2021","unstructured":"Kiryu Y (2021) Potential for big data analysis using AI in the field of clinical pharmacy. Yakugaku Zasshi 141:179\u2013185. https:\/\/doi.org\/10.1248\/yakushi.20-00196-4","journal-title":"Yakugaku Zasshi"},{"key":"10605_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204648","volume":"13","author":"K Hosomi","year":"2018","unstructured":"Hosomi K, Fujimoto M, Ushio K, Mao L, Kato J, Takada M (2018) An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs. PLoS One 13:e0204648. https:\/\/doi.org\/10.1371\/journal.pone.0204648","journal-title":"PLoS One"},{"key":"10605_CR17","doi-asserted-by":"publisher","unstructured":"Matsuo H, Endo K, Tanaka H, Onoda T, Ishii T (2024) Fact-finding survey and exploration of preventive drugs for antineoplastic drug-induced oral mucositis using the Japanese Adverse Drug Event Report Database. Sci Pharm 92:34. https:\/\/doi.org\/10.3390\/scipharm92020034","DOI":"10.3390\/scipharm92020034"},{"issue":"1","key":"10605_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EPEP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek EPEP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10605_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/sj.tpj.6500412","volume":"7","author":"JJ Chen","year":"2007","unstructured":"Chen JJ, Wang SJ, Tsai CA, Lin CJ (2007) Selection of differentially expressed genes in microarray data analysis. Pharmacogenomics J 7(3):212\u2013220. https:\/\/doi.org\/10.1038\/sj.tpj.6500412","journal-title":"Pharmacogenomics J"},{"key":"10605_CR20","first-page":"278","volume":"134","author":"ABW Kennedy","year":"1898","unstructured":"Kennedy ABW, Sankey HR (1898) The thermal efficiency of steam engines. Report of the committee appointed to the council upon the subject of the definition of a standard or standards of thermal efficiency for steam engines: with an introductory note (including appendixes and plate at back of volume). Minutes Proc Inst Civ Eng 134:278\u2013312","journal-title":"Minutes Proc Inst Civ Eng"},{"key":"10605_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejca.2017.07.029","volume":"84","author":"Y Shi","year":"2017","unstructured":"Shi Y, Lin P, Ho EY, Nock CJ (2017) Nivolumab-associated nausea and vomiting as an immune adverse event. Eur J Cancer 84:367\u2013369. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.029","journal-title":"Eur J Cancer"},{"issue":"11","key":"10605_CR22","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","volume":"27","author":"A Hegde","year":"2021","unstructured":"Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS (2021) A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies. Clin Cancer Res 27(11):3050\u20133060. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4118","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10605_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","volume":"21","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS (2015) Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21(4):712\u2013720. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2468","journal-title":"Clin Cancer Res"},{"key":"10605_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ (2013) A severe case of ipilimumab-induced guillain-barr\u00e9Guillain-Barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36:77\u201378. https:\/\/doi.org\/10.1097\/CJI.0b013e31827807dd","journal-title":"J Immunother"},{"key":"10605_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1223929","volume":"14","author":"K Krawczyk","year":"2023","unstructured":"Krawczyk K, \u015aladowska K, Holko P, Kawalec P (2023) Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Front Pharmacol 14:1223929. https:\/\/doi.org\/10.3389\/fphar.2023.1223929","journal-title":"Front Pharmacol"},{"key":"10605_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33:244\u2013250. https:\/\/doi.org\/10.1200\/JCO.2014.56.2728","journal-title":"J Clin Oncol"},{"issue":"2","key":"10605_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1634\/theoncologist.8-2-187","volume":"8","author":"FM Schnell","year":"2003","unstructured":"Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8(2):187\u2013198. https:\/\/doi.org\/10.1634\/theoncologist.8-2-187","journal-title":"Oncologist"},{"key":"10605_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000087979","volume":"69","author":"M Aapro","year":"2005","unstructured":"Aapro M (2005) 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69:97\u2013109. https:\/\/doi.org\/10.1159\/000087979","journal-title":"Oncology"},{"issue":"4","key":"10605_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1517\/14740338.5.4.553","volume":"5","author":"MW Saif","year":"2006","unstructured":"Saif MW, Mehra R (2006) Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 5(4):553\u2013566. https:\/\/doi.org\/10.1517\/14740338.5.4.553","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"10605_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592\u2013603. https:\/\/doi.org\/10.1038\/nrc2442","journal-title":"Nat Rev Cancer"},{"key":"10605_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/1547691X.2021.1984617","volume":"18","author":"S Ito","year":"2021","unstructured":"Ito S, Miwa K, Hattori C, Aida T, Tsuchiya Y, Mori K (2021) Highly sensitive in vitro cytokine release assay incorporating high-density preculture. J Immunotoxicol 18:136\u2013143. https:\/\/doi.org\/10.1080\/1547691X.2021.1984617","journal-title":"J Immunotoxicol"},{"key":"10605_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1744806918797042","author":"M Bechakra","year":"2018","unstructured":"Bechakra M, Nieuwenhoff MD, van Rosmalen J, Groeneveld GJ, Scheltens-de Boer M, Sonneveld P, van Doorn PA, de Zeeuw CI, Jongen JL (2018) Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol Pain. https:\/\/doi.org\/10.1177\/1744806918797042","journal-title":"Mol Pain"},{"key":"10605_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5649\/jjphcs.36.270","volume":"36","author":"D Makieda","year":"2010","unstructured":"Makieda D, Hisaeda S, Kinoshita H, Uchida M, Ikesue H, Mishima K, Watanabe H, Sueyasu M, Miyamoto T, Egashira N, Oishi R (2010) Investigation of adverse drug reactions in bortezomib therapy for relapsed multiple myeloma. Jpn J Pharm Health Care Sci 36:270\u2013276. https:\/\/doi.org\/10.5649\/jjphcs.36.270","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"10605_CR34","unstructured":"Wang K, Schumacher W (2003) Effects of BMS\u2014354825 on platelet function. BMS\u2014Document control No. 930004015. Bristol-Myers Squibb Company, New York."},{"key":"10605_CR35","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen M-L, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl-phenyl-2-(6-(4-[2-hydroxy-ethyl]-piperazin-1-yl)-2-methylpyrimidin-4\u2013ylamino thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658\u20136661. https:\/\/doi.org\/10.1021\/jm049486a","journal-title":"J Med Chem"},{"key":"10605_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, Tohyama O, Semba T, Yamaguchi A, Hoshi SS, Mimura F, Haneda T, Fukuda Y, Kamata JI, Takahashi K, Matsukura M, Wakabayashi T, Asada M, Nomoto KI, Watanabe T, Dezso Z, Yoshimatsu K, Funahashi Y, Tsuruoka A (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18. https:\/\/doi.org\/10.1186\/2045-824X-6-18","journal-title":"Vasc Cell"},{"key":"10605_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.taap.2014.04.015","volume":"278","author":"L Fan","year":"2014","unstructured":"Fan L, Hu L, Yang B, Fang X, Gao Z, Li W, Sun Y, Shen Y, Wu X, Shu Y, Gu Y, Wu X, Xu Q (2014) Erlotinib promotes endoplasmic reticulum stress-mediated injury in the intestinal epithelium. Toxicol Appl Pharmacol 278:45\u201352. https:\/\/doi.org\/10.1016\/j.taap.2014.04.015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10605_CR38","unstructured":"https:\/\/www.taiho.co.jp\/medical\/brand\/ts-1\/cse\/cnt01.html. Accessed 05 Apr 2025"},{"key":"10605_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070775","volume":"14","author":"E Pankiv","year":"2024","unstructured":"Pankiv E, Nghiem J, Albornoz AE, Rana M, Petre MA, Englesakis M, Hayes J, McDonnell C, Aoyama K (2024) Appraising and highlighting gaps among prophylactic intervention studies for reducing the incidence of postoperative nausea and vomiting in children: a systematic review. BMJ Open 14:e070775. https:\/\/doi.org\/10.1136\/bmjopen-2022-070775","journal-title":"BMJ Open"},{"key":"10605_CR40","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1345\/aph.10219","volume":"36","author":"WK Nelson","year":"2002","unstructured":"Nelson WK, Rayback PA, Quinones R, Giller RH (2002) Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients. Ann Pharmacother 36:1360\u20131365. https:\/\/doi.org\/10.1345\/aph.10219","journal-title":"Ann Pharmacother"},{"key":"10605_CR41","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40264-023-01351-y","volume":"46","author":"M Gustafsson","year":"2023","unstructured":"Gustafsson M, Matos C, Joaquim J, Scholl J, van Hunsel F (2023) Adverse drug reactions to opioids: a study in a national pharmacovigilance database. Drug Saf 46:1133\u20131148. https:\/\/doi.org\/10.1007\/s40264-023-01351-y","journal-title":"Drug Saf"},{"key":"10605_CR42","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","volume":"9","author":"K Nomura","year":"2015","unstructured":"Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M (2015) Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Devel Ther 9:3031\u20133041. https:\/\/doi.org\/10.2147\/DDDT.S81998","journal-title":"Drug Des Devel Ther"},{"key":"10605_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1248\/yakushi.20-00196-1","volume":"141","author":"T Sakai","year":"2021","unstructured":"Sakai T (2021) Role and applicability of spontaneous reporting databases in medical big data. Yakugaku Zasshi 141:165\u2013168. https:\/\/doi.org\/10.1248\/yakushi.20-00196-1","journal-title":"Yakugaku Zasshi"},{"key":"10605_CR44","first-page":"1","volume":"6","author":"J Weber","year":"1984","unstructured":"Weber J (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res 6:1\u20137","journal-title":"Adv Inflamm Res"},{"key":"10605_CR45","first-page":"135","volume":"21","author":"H Urushihara","year":"2020","unstructured":"Urushihara H (2020) Basic dos and don\u2019ts in applying signal detection methods to spontaneous reporting systems databases. Jpn J Drug Inf 21:135\u2013141","journal-title":"Jpn J Drug Inf"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10605-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:49:00Z","timestamp":1778683740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10605-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10605"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10605-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not sought because this was a database-related observational study with no direct access to any research participants. All the results of this study were obtained from the JADER database, and all data obtained from the database were fully anonymized by the relevant regulatory authorities prior to access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}